181 related articles for article (PubMed ID: 9685172)
21. The efficacy of recombinant thrombopoietin in murine and nonhuman primate models for radiation-induced myelosuppression and stem cell transplantation.
Wagemaker G; Neelis KJ; Hartong SC; Wognum AW; Thomas GR; Fielder PJ; Eaton DL
Stem Cells; 1998; 16(6):375-86. PubMed ID: 9831863
[TBL] [Abstract][Full Text] [Related]
22. Cytokines for the treatment of thrombocytopenia.
Ciurea SO; Hoffman R
Semin Hematol; 2007 Jul; 44(3):166-82. PubMed ID: 17631181
[TBL] [Abstract][Full Text] [Related]
23. Thrombopoietin concentrations in peripheral blood correlated with platelet numbers in two patients with thrombocytopenia by chronic graft-versus-host disease.
Hirayama Y; Sakamaki S; Tsuji Y; Sagawa T; Chiba H; Matsunaga T; Kuroda H; Kusakabe T; Akiyama T; Kato J; Niitsu Y
Am J Hematol; 2003 Aug; 73(4):285-9. PubMed ID: 12879435
[TBL] [Abstract][Full Text] [Related]
24. The effect of a novel, small non-peptidyl molecule butyzamide on human thrombopoietin receptor and megakaryopoiesis.
Nogami W; Yoshida H; Koizumi K; Yamada H; Abe K; Arimura A; Yamane N; Takahashi K; Yamane A; Oda A; Tanaka Y; Takemoto H; Ohnishi Y; Ikeda Y; Miyakawa Y
Haematologica; 2008 Oct; 93(10):1495-504. PubMed ID: 18728031
[TBL] [Abstract][Full Text] [Related]
25. Changes in endogenous TPO levels during mobilization chemotherapy are predictive of CD34+ megakaryocyte progenitor yield and identify patients at risk of delayed platelet engraftment post-PBPC transplant.
Maharaj D; Steinberg JP; Gouvea JV; Gieser PW
Bone Marrow Transplant; 1999 Mar; 23(6):539-48. PubMed ID: 10217183
[TBL] [Abstract][Full Text] [Related]
26. In vivo biological effects of various forms of thrombopoietin in a murine model of transient pancytopenia.
Thomas GR; Thibodeaux H; Errett CJ; Mathias J; Marian M; Meng G; Vandlen RL; Eaton DL
Stem Cells; 1996; 14 Suppl 1():246-55. PubMed ID: 11012228
[TBL] [Abstract][Full Text] [Related]
27. The role of recombinant interleukin 11 in megakaryocytopoiesis.
Turner KJ; Neben S; Weich N; Schaub RG; Goldman SJ
Stem Cells; 1996; 14 Suppl 1():53-61. PubMed ID: 11012203
[TBL] [Abstract][Full Text] [Related]
28. Clinical studies with megakaryocyte growth and development factor (Mpl-ligand).
Begley CG
Thromb Haemost; 1997 Jul; 78(1):42-6. PubMed ID: 9198125
[TBL] [Abstract][Full Text] [Related]
29. Thrombopoietin accelerates platelet, red blood cell, and neutrophil recovery in myelosuppressed mice.
Grossmann A; Lenox J; Ren HP; Humes JM; Forstrom JW; Kaushansky K; Sprugel KH
Exp Hematol; 1996 Aug; 24(10):1238-46. PubMed ID: 8765500
[TBL] [Abstract][Full Text] [Related]
30. Phase 1 study of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in breast cancer patients after autologous peripheral blood progenitor cell (PBPC) transplantation.
Bolwell B; Vredenburgh J; Overmoyer B; Gilbert C; Chap L; Menchaca DM; Cruickshank S; Glaspy J
Bone Marrow Transplant; 2000 Jul; 26(2):141-5. PubMed ID: 10918423
[TBL] [Abstract][Full Text] [Related]
31. Physician Education: Myelodysplastic Syndrome.
Yoshida Y
Oncologist; 1996; 1(4):284-287. PubMed ID: 10388004
[TBL] [Abstract][Full Text] [Related]
32. Do the preclinical effects of thrombopoietin correlate with its in vitro properties?
Kaushansky K; Broudy VC; Sitnicka E; Lofton-Day C; Grossmann A; Sprugel K
Stem Cells; 1996; 14 Suppl 1():108-11. PubMed ID: 11012209
[TBL] [Abstract][Full Text] [Related]
33. [A multi-center clinical trial of recombinant human thrombopoietin in the treatment of chemotherapy-induced thrombocytopenia in patients with solid tumor].
Bai CM; Xu GX; Zhao YQ; Han SM; Shan YD
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2004 Aug; 26(4):437-41. PubMed ID: 15379272
[TBL] [Abstract][Full Text] [Related]
34. The role of platelet growth factors in cancer therapy.
Clarke K; Basser RL
Stem Cells; 1996; 14 Suppl 1():274-80. PubMed ID: 11012231
[TBL] [Abstract][Full Text] [Related]
35. Flt3 ligand and thrombopoietin serum levels during peripheral blood stem cell mobilization with chemotherapy and recombinant human glycosylated granulocyte colony-stimulating factor (rhu-G-CSF, lenograstim) and after high-dose chemotherapy.
Bojko P; Pawloski D; Stellberg W; Schröder JK; Seeber S
Ann Hematol; 2002 Sep; 81(9):522-8. PubMed ID: 12373354
[TBL] [Abstract][Full Text] [Related]
36. Recombinant human thrombopoietin in myelosuppressive chemotherapy.
Vadhan-Raj S
Oncology (Williston Park); 2001 Jul; 15(7 Suppl 8):35-8. PubMed ID: 11497230
[TBL] [Abstract][Full Text] [Related]
37. AKR-501 (YM477) in combination with thrombopoietin enhances human megakaryocytopoiesis.
Fukushima-Shintani M; Suzuki K; Iwatsuki Y; Abe M; Sugasawa K; Hirayama F; Kawasaki T
Exp Hematol; 2008 Oct; 36(10):1337-42. PubMed ID: 18619724
[TBL] [Abstract][Full Text] [Related]
38. [Clinical tolerance test of recombinant human thrombopoietin].
Zhao Y; Jiang J; Jiao L
Zhonghua Yi Xue Za Zhi; 2001 Dec; 81(24):1508-11. PubMed ID: 16200777
[TBL] [Abstract][Full Text] [Related]
39. Effects of Mpl ligands on platelet production and function in nonhuman primates.
Harker LA; Marzec UM; Kelly AB
Stem Cells; 1998; 16 Suppl 2():107-19. PubMed ID: 11012183
[TBL] [Abstract][Full Text] [Related]
40. [The clinical study of recombinant human thrombopoietin in the treatment of chemotherapy-induced severe thrombocytopenia].
Bai CM; Zou XY; Zhao YQ; Han SM; Shan YD;
Zhonghua Yi Xue Za Zhi; 2004 Mar; 84(5):397-400. PubMed ID: 15061993
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
